Interleukin – 17 and Interleukin-10 as Inflammatory and Prevention Biomarkers in Periimplant Diseases

Abstract
Background: Periimplant diseases are inflammatory diseases. Thus, the level of preinflammatory cytokines which has important role in the inflammation processes can consider as biochemical markers for early diagnosis and prevention of periimplant diseases. The aim of this study was to determine and compare the level of interleukin (IL)-17 and IL-10 in patients with periimplant mucositis and periimplantitis. Methods: This case–control study was conducted on 51 patients with implants which were loaded at least 1 year previously, 17 patients with periimplant mucositis, 17 patients with periimplantitis, and 17 individuals with healthy implants. After clinical examination, gingival crevicular fluid sampling was carried out by paper point number 25 for 4 min and the mean value of IL-17, IL-10 in samples was measured using enzyme linked immunosorbent assay (ELISA), least square differences (LSD) reader in laboratory. The data was analyzed using statistical software SPSS 22. Quantitative analysis was done using One-way analysis of variance (ANOVA) test and LSD past test. Results: The results of analysis showed that there was a significant difference in the mean value of IL-17 and IL-10 among the three study groups (P < 0.001). Individuals with healthy implants showed a significant lower level of IL-17 than patients with periimplantitis (P = 0.001) and for patients with periimplantitis, the level of IL-17 was significantly lower than that of patients with periimplant mucositis (P < 0.001) and IL-10 level was significantly lower in mucositis than periimplantitis (P < 0.001). Conclusions: The level of IL-17 and IL-10 increased in patients with periimplant compared to individuals with healthy periimplant tissues and the results showed that the highest concentrations of IL-17 and IL-10 were observed in patients with periimplant mucositis and periimplantitis, respectively.

Keywords: Interleukin-10, interleukin-17, mucositis, periimplantitis

Introduction
Implantology is considered as an important field of study in modern dentistry. Implants as the useful treatment provides the opportunity to restore the function and esthetic to the patients. However, like any other treatment, the complications and adverse consequences are considered as an integral part of this treatment as well. Among these complications, occurrence of inflammation and infection in tissues around the implant are more important.

Tissues around the implants are prone to bacterial infection, which causes inflammation and development of periimplant mucositis and periimplantitis, consequently resulting in periodontal diseases like gingivitis and chronic periodontitis.[1]

Mucositis is a reversible inflammatory lesion caused by microbial plaque and is limited to the soft tissue around dental implants and has no bone involvement. If the inflammation progress reaches to the bone, mucositis turns into periimplantitis, which is diagnosed using radiographic images prepared by radiolucency around the implant in radiographic image.[2]

In periodontal diseases, cytokines are released in response to bacterial invasion into periodontal tissues, which increase the immune responses and will be effective in regulation of inflammatory-immune responses and infection suppression fundamentally.[3]

Belibasakis[4] in a study on human biopsies showed that periimplantitis and periodontitis lesions had common microbiological and immunological characteristics.

Al-Majid et al.[5] indicated that the analysis of the disease-specific oral and systemic biomarkers in saliva and oral fluids exerts the strong potential to serve as a useful adjunctive diagnostic and preventive.

How to cite this article: Farhad SZ, Rezazadeh F, Mohammadi M. Interleukin – 17 and interleukin-10 as inflammatory and prevention biomarkers in periimplant diseases. Int J Prev Med 2019;10:137.
biotechnological tool in periodontal and periimplant diseases, also Zani et al.,[6] in their study suggested that periimplant crevicular fluid biomarkers might be helpful in distinguishing healthy periimplant from diseased one.

Cytokines cause tissue destruction and bone loss through activating collagenase, osteoclast activating enzymes, and other destructive enzymes.[7] Duarte et al.[8] in their systematic review study mentioned that proinflammatory cytokines specially interleukin (IL)-1, IL-6, IL-12, IL-17, and tumor necrosis factor alpha (TNFα) were among the cytokines which have been studied most commonly.

IL-17 is a proinflammatory cytokine that increases in periodontal disease and has an important role in the regulation of other destructive cytokines.[9]

The findings of a recent study conducted in 2015 by Chitrapriya et al.[10] on biopsy samples revealed that the level of IL-17 increased through the inflammation occurring in periodontal tissues.

Also, de Araujo et al.[11] in a study on periimplant tissue showed that the level of IL-17 increased through the inflammation occurring in these tissues.

Like many other inflammatory cytokines, IL-17 plays both protective and pathogenic role in the immune system.[12] IL-17 has a central role in starting and sustaining the immune responses[13] and plays an important role in host defense against various microorganisms.[14]

IL-10 is a human cytokine influencing immunoregulation and inflammation. It also has potent anti-inflammatory properties that play a crucial role in limiting immune response to pathogens, thereby preventing damage to the host.[15] Ghighi et al.[16] in their study showed that the level of IL-10 increased significantly in periimplantitis tissues. Tzach-Nahman et al.[17] in a study on oral infection with Porphyromonas gingivalis in mice had implant showed the bone loss and a shift in cytokines expression of gingival. In 2016, Severino et al.[18] found that the level of IL-17 was significantly higher in patients with periimplantitis and periimplant mucositis but there were no of the level of IL-10 between experimental groups. The result of the study by Ata-Ali et al.[19] suggested that there was a relationship between the concentration of cytokines such as IL-10 and the inflammatory response in periimplant tissues.

Considering that IL-17 and IL-10 are among the new cytokines that has not been investigated extensively in prior researches and due to the contradictory results of the previous studies, for example Kadkhodazadeh et al. in 2013[20] revealed no significant role for IL-17 in the development of periodontitis and periimplantitis and according to the fact that, for more accurate diagnostics of periodontal disease activity and progression using a chair-side test or other similar test may help to reduce oral health care costs by reducing patient overtreatment, improving patient outcome, and reducing the need for complex periodontal therapies as well as the importance of ILs as biochemical marker for early diagnosis and early prevention of periimplant disease, the present study was designed to determine and compare the levels of IL-17 and IL-10 in patients with mucositis, periimplantitis, and also in individuals with healthy gingiva.

Methods

This case–control study was conducted on 17 patients with mucositis, 17 patients with periimplantitis, and 17 individuals with healthy implants, who were aged between 35 and 65 years old, who were selected according to the criterion stating that the time interval ranging between 1 and 5 years should passed since the restoring of the prosthesis on their implants, among patients referred to dental clinic affiliated with Islamic Azad University, in Isfahan province, Iran.

The patients with mucositis had symptoms including inflammation, pocket depth of less than 4 mm, and maximum bone loss to the first thread.[2] The patients with periimplantitis had symptoms such as a probing depth (PD) more than 4 mm and maximum bone loss to the second thread, along with signs of inflammation in the soft tissues.[21] The X-ray images taken at the time of screwing the healing showed the bone height was positioned at least equal to the first thread.

The patients with certain systemic diseases, patients using certain drugs, pregnant and lactating women, patients using tobacco and alcohol, patients who had the history of using broad-spectrum antibiotics in the last 6 months, patients who had the history of periodontal treatments in the previous year, patients with plaque index (PI) of more than 40%, were excluded from the study. Ultimately, according to these criteria from 94 patients, 51 patients were included in this study.

After completing an informed consent form, doing preliminary examinations, completion of periodontal chart and taking radiographic images for each patient, the clinical parameters, including bleeding on probing (BOP), PD, and PI were measured by one observer and were recorded in the specific forms.[3]

After washing the mouth, it was dried completely and then, the examined area was isolated. After that, the GCF samples were taken from two areas around the implant (the deepest sulcus or periodontal pocket) using paper point No. 25 for 4 min. Then, the paper points were transferred into the test tubes containing special transport medium and were transferred to special chambers immediately in the laboratory while maintaining the cold chain (2–5°C), and then, they were stored at −70°C.

Then, all the solution samples, which were frozen, were melted until reaching to room temperature. Samples were
Farhad, et al.: IL-17 and IL-10 as prevention biomarkers in periimplant diseases

The mean value of IL-17 was significantly lower in healthy control group than mucositis group (P < 0.001), and it was also significantly lower in healthy control group than mucositis group (P < 0.001). Thus, the level of IL-17 was found to be significantly higher in mucositis group than other groups.

The mean value of IL-10 was significantly lower in healthy control group than mucositis group (P < 0.001), and it was also significantly lower in mucositis group than periimplantitis group (P < 0.001), and it was also significantly lower in healthy control group than mucositis group (P < 0.001). Thus, the level of IL-10 was found to be significantly higher in mucositis group than other groups.

Table 1: Subject’s age and gender

| Variables | Mucositis | Peri-implantitis | Implants healthy | P  |
|-----------|-----------|-----------------|-----------------|----|
| Age (mean±SD) | 46±7.0 | 49.3±7.89 | 49.3±7.89 | 0.31 |
| Sex (No %) |  |  |  |  |
| Men | 6 (35.29) | 9 (52.94) | 7 (41.17) | 0.53 |
| Women | 1 (47.05) | 8 (47.05) | 10 (58.82) |  |

Table 2: The average of Bleeding on Probing (BOP), Probing Depth (PD)

| Variables | Mucositis | Peri-implantitis | Implants healthy | P  |
|-----------|-----------|-----------------|-----------------|----|
| BOP | 77±16.86 | 85.73±13065 | 0±0 | 0.001 |
| PD | 2.53±0.64 | 6.02±1.12 | 2.10±0.80 | 0.01 |

Table 3: The average value of IL-17 and IL-10 (ng/dl)

| Variables | Mucositis | Peri-implantitis | Implants healthy | P  |
|-----------|-----------|-----------------|-----------------|----|
| IL-17 | 57.7±14.6 | 19.9±10.3 | 5.8±0.5 | 0.001 |
| IL-10 | 38±10.3 | 56.5±16.4 | 7.7±3.0 | 0.001 |

Discussion

Periimplant inflammatory diseases are considered as the infectious diseases involving the tissues around the osseointegrated implants.[22] Following the presence of bacterial biofilm, innate and adaptive immune systems are activated, which is followed by the production and secretion of inflammatory mediators with the purpose of protection; however, tissue damage occurs subsequently. The presence and function of many of these inflammatory mediators has been proven in development of periodontal diseases; however, there is a need for further studies due to the complex network of the mediators and overlaps existing regarding their functions.[3]

According to similarities and differences between periimplant and periodontal tissues and also between periimplant and periodontal diseases, a number of studies have recently focused on the mechanisms of development and progress of periimplant diseases involving the immune system and inflammatory mediators. The results of the study by Recker et al.[23] in 2016 pointed to the difference...
in expression level of specific biomarkers in GCF compared to that of periimplant crevicular fluid in periodontal maintenance patients, which has been considered as an critical information to be evaluated before applying these fluids as diagnostic tools.

IL-17 is a proinflammatory cytokine that plays both protective and pathogenic roles in the immune system. The most important role of IL-17 in immunity against infection is performed by influencing on neutrophils at the site of infection and activating the macrophages. Due to infectious origin of periodontal diseases, a number of previous studies have been recently focused on investigating the presence and action of IL-17 in these diseases.

The present study investigated the level of IL-17 and IL-10 in the periimplant diseases (mucositis and periimplantitis) and compared it with those in implants surrounded by healthy tissues. The results of the present study showed that there was a significant difference in the mean value of IL-17 and IL-10 between healthy control, mucositis, and periimplantitis groups. The findings of the study indicated that the mean value of IL-17 was significantly higher in mucositis group than the two other groups and also there was a significant increase in the mean value of IL-10 in periimplantitis group than the two other groups. No quantitative study has been done on the level of IL-17 and IL-10 in patients with mucositis and comparing it with those of healthy and periimplantitis groups in the chain of investigations carried out on the role of IL-17 and IL-10 in development of periimplant diseases. Therefore, this study was the first study conducted in this regard. However, there is a need for further researches in order to study this subject extensively. Due to the proximity of mucositis to gingivitis regarding their pathogenesis, the results of this study can be compared with the results of studies on gingivitis. The results of the current study are consistent with the results of the studies by Oda et al. and Chitrapiiya et al. stated that the level of IL-17 was higher in gingivitis than that of periodontitis and healthy control groups. The difference in the results is attributed to the methods used in the above-mentioned studies, such that the method used in above studies was an invasive biopsy method, while in the present study, the patient's GCF sampling was done using paper point. Likewise, Mardegan et al. showed that there was no difference in the level of IL-17 m-RNA between the healthy control and periimplantitis groups, but their study investigated the level of m-RNA using real-time polymerase chain reaction (PCR) to determine the profile of IL-17 gene expression.

Considering the role of IL-17 in starting and sustaining the immune responses as well as the accumulating and activating the neutrophils and macrophages, these results are not far-fetched and they emphasized proinflammatory properties of IL-17. In case of level of IL-17 in periimplantitis, the results of the study were consistent with the results of the study by Severino et al. in 2011 conducted on 23 patients with periimplantitis. The results also reported an increase in the level of IL-17 in the GCF of patients with periimplantitis compared to the individuals with healthy implants. Furthermore, the results of the present study are consistent with the results of the studies by Darabi et al. and Fonseca et al. and Severino et al. in 2016 conducted on 40 patients, showing that the level of IL-17 was significantly higher in periimplantitis and mucositis groups and they hypothesized that this cytokine was also contributing to the inflammatory process observed in these disease.

In a study by Johnson et al. in 2004, the level of IL-17 was measured in pockets with different depths around natural teeth, and the highest level of IL-17 was found in pockets with 4–5 mm depth. The results of the study showed that the level of IL-17 reduced in the presence of higher pocket depth. According to the severity of inflammation and infiltration of more inflammatory cells to the sites of infection in periimplant diseases compared to periodontal diseases, as well as considering that the present study was focused on patients with PDs of less than 4 mm in the mucositis group and since the highest level of IL-17 was observed in this group, the results of the study by Johnson et al. can be considered somewhat consistent with those of the present study. The results of the present study showed that the average level of IL-17 reduced while changing from mucositis to periimplantitis. According to the infectious origin of inflammation in both diseases, it is suggested to study on the probability of negative feedback through dynamic mechanisms and different regulatory systems in the production of IL-17 path way.

Different regulatory mechanisms such as STAT-3 (a transcription factor that is required critically for determining the level of Interlukin-17) cells have been mentioned so far for describing the role of IL-17.

Regarding the mean value of IL-10 determined in this study, it was concluded that Ghiglhi et al. suggested that periimplant and periodontitis connective tissues exhibit differences in response to nonsurgical treatment and stated that IL-10 significantly increase in periimplant tissues. Casado et al. in their research on periimplant disease stated that there was an increase in mean value of IL-10 in periimplantitis. Ata-Ali et al. in evaluation of clinical and microbiological properties of periimplant tissues concluded that there was a significant increase in the mean value of IL-10 in periimplantitis. Likewise, Severino et al. showed there was no significant differences in the mean value of IL-10 in periimplant disease. Andreiotelli et al. in genetic evaluation reported that polymorphism IL-10 had no role in implant disease and failure. Such differences in results might be due to racial differences, and various type of study design, furthermore, the differences in measurement technique, and personal habits.

Since IL-17 and IL-10 is among the cytokines studied in recent years and few studies have been conducted on the
role of interleukins in the pathogenesis of periodontal diseases, and periimplant diseases in particular, therefore there is a need for further research in order to obtain definitive results in this regard.

Conclusions
A key characteristic of active periodontal and periimplant diseases is the sustained pathological elevation and activation of inflammatory biomarkers in periodontal and periimplant tissues, which are reflected in oral fluids. Moreover, inflammatory cytokines can also serve as a predictive and preventive biological tool to indicate and time preventive intervention.

Acknowledgments
Authors express their gratitude and respect to all the patients who were volunteered to participate in this study. We also appreciate all attending professors, residents, and staffs of the dental clinic affiliated with Islamic Azad University in Isfahan, Iran for their kind contribution in this project.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Received: 28 Jan 19 Accepted: 06 Mar 19
Published: 12 Aug 19

References
1. Liljenberg B, Gualini F, Berglundh T, Tonetti M, Lindhe J. Some characteristics of the ridge mucosa before and after implant installation. A prospective study in humans. J Clin Periodontol 1996;23:1008-13.

2. The American Academy of Periodontology. Peri-implant mucositis and peri-implantitis: A current understanding of their diagnoses and clinical implications. J Periodontol 2013;84:436-43.

3. Newman M, Takei H, Klokkevold P, Carranza F. Carranza’s Clinical Periodontology. 12th ed. St. Louis: Saunders Elsevier; 2015.

4. Belibasakis GN. Microbiological and immune-pathological aspects of peri-implant diseases. Arch Oral Biol. 2014;59:66-72.

5. Al-Majid A, Alassiri S, Rathnayake N, Tervahartiala T, Gieselmann DR, Sorsa T. Matrix metalloproteinase-8 as an inflammatory and prevention biomarker in periodontal and peri-implant diseases. Int J Dent 2018;2018:7891323.

6. Zani SR, Themeli M, Shibli JA, Teixeira ER, de Oliveira Mairink R, Onuma T, et al. Peri-implant mucosal fluid biomarkers as discriminants of peri-implant health and disease. J Clin Periodontol 2016;43:825-32.

7. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003;38:605-14.

8. Duarte PM, Serra CR, Miranda TS, Zanatta LC, Bastos MF, Favari M, et al. Could cytokine levels in the peri-implant crevicular fluid be used to distinguish between healthy implants and implants with peri-implantitis? A systematic review. J Periodontal Res 2016;51:689-98.

9. Severino VO, Napimoga MH, de Lima Pereira SA. Expression of IL-6, IL-10, IL-17 and IL-8 in the peri-implant crevicular fluid of patients with peri-implantitis. Arch Oral Biol 2011;56:823-8.

10. Chitrupriya MN, Rao SR, Lavu V. Interleukin-17 and interleukin-18 levels in different stages of inflammatory periodontal disease. J Indian Soc Periodontol 2015;19:14-7.

11. de Araujo MF, Filho AF, da Silva GP, de Melo ML, Napimoga MH, Rodrigues DB, et al. Evaluation of peri-implant mucosa: Clinical, histopathological and immunological aspects. Arch Oral Biol 2014;59:470-8.

12. Cheng WC, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 2014;41:541-9.

13. Yu JJ, Gaffen SL. Interleukin-17: A novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 2008;13:70-7.

14. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005;73:617-21.

15. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012;32:23-63.

16. Ghiggi M, Llorens A, Baroukh B, Chausain C, Bouchard P, Gosset M. Differences between inflammatory and catabolic mediators of peri-implantitis and periodontitis lesions following initial mechanical therapy: An exploratory study. J Periodontal Res 2018; 53:29-39.

17. Tzach-Nahman R, Mizraji G, Shapira L, Nussbaum G, Wilensky A. Oral infection with Porphyromonas gingivalis induces peri-implantitis in a murine model: Evaluation of bone loss and the local inflammatory response. J Clin Periodontol 2017;44:739-48.

18. Severino VO, Beghini M, de Araújo MF, de Melo MLR, Miguel CB, Rodrigues WF, et al. Expression of IL-6, IL-10, IL-17 and IL-33 in the peri-implant crevicular fluid of patients with peri-implant mucositis and peri-implantitis. Arch Oral Biol 2016;72:194-9.

19. Ata-Ali J, Flichy-Fernández AJ, Alegre-Domingo T, Ata-Ali F, Palacio J, Peñarrocha-Diago M. Clinical, microbiological, and immunological aspects of healthy versus peri-implantitis tissue in full arch reconstruction patients: A prospective cross-sectional study. BMC Oral Health 2015;15:43.

20. Kadkhodazadeh M, Baghani Z, Ebadian AR, Youssefi N, Mehdizadeh AR, Azimi N. IL-17 gene polymorphism is associated with chronic periodontitis and peri-implantitis in Iranian patients: A cross-sectional study. Immunol Invest 2013;42:156-63.

21. Darabi E, Kadkhoda Z, Amirzargar A. Comparison of the levels of tumor necrosis factor-alpha and interleukin-17 in gingival crevicular fluid of patients with peri-implantitis and a control group with healthy implants. Iran J Allergy Asthma Immunol 2013;12:75-80.

22. Khammissa RA, Feller L, Meyerov R, Lemmer J. Peri-implant mucositis and peri-implantitis: Clinical and histopathological characteristics and treatment. SADJ 2012;67:122, 4-6.

23. Recker EN, Avila-Ortiz G, Fischer CL, Pagan-Rivera K, Brogden KA, Dawson DV, et al. A cross-sectional assessment of biomarker levels around implants versus natural teeth in periodontal maintenance patients. J Periodontol 2015;86:264-72.

24. Oda T, Yoshie H, Yamazaki K. Porphyromonas gingivalis antigen
preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. Oral Microbiol Immunol 2003;18:30-6.

25. Mardegan GP, Shibli JA, Roth LA, Faveri M, Giro G, Bastos MF. Transforming growth factor-beta, interleukin-17, and IL-23 gene expression profiles associated with human peri-implantitis. Clin Oral Implants Res 2017;28:e10-5.

26. Fonseca FJ, Moraes Junior M, Lourenco EJ, Teles Dde M, Figueredo CM. Cytokines expression in saliva and peri-implant crevicular fluid of patients with peri-implant disease. Clin Oral Implants Res 2014;25:e68-72.

27. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol. 2004;75:37-43.

28. Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CM. A negative feedback loop mediated by STAT3 limits human Th17 responses. J Immunol 2014;193:1142-50.

29. Casado PL, Canullo L, de Almeida Filardy A, Granjeiro JM, Barboza EP, Leite Duarte ME. Interleukins 1β and 10 expressions in the periimplant crevicular fluid from patients with untreated periimplant disease. Implant Dent 2013;22:143-50.

30. Andreiotelli M, Koutayas SO, Madianos PN, Strub JR. Relationship between interleukin-1 genotype and peri-implantitis: A literature review. Quintessence Int 2008;39:289-98.